A significant drawback of the exogenous administration of insulin to diabetics is the non-physiological profile of insulin action resulting in the insufficient suppression of hepatic glucose production, which is the main contributing factor to diabetic hyperglycemia under fasting conditions and the basis of the challenge to restore a more physiological glucose profile in diabetes. The insulin receptor (IR) exists in two alternatively spliced variants, IR-A and IR-B, with different tissue distribution. While peripheral tissues contain different proportions of both isoforms, hepatic cells almost exclusively contain IR-B. In this respect, IR-B-selective insulin analogs would be of great interest for their potential to restore more natural metabolic homeostasis in diabetes. Recent advances in the structural biology of insulin and IR have provided new clues for understanding the interaction of both proteins. This article discusses and offers some structural perspectives for the design of specific insulin analogs with a preferential binding to IR-B.

Institute of Organic Chemistry and Biochemistry Czech Academy of Sciences Prague Czechia

Zobrazit více v PubMed

Zaykov AN, Mayer JP, DiMarchi RD. Pursuit of a perfect insulin. Nat Rev Drug Discov (2016) 15:425–39.10.1038/nrd.2015.36 PubMed DOI

Brange J, Volund A. Insulin analogs with improved pharmacokinetic profiles. Adv Drug Deliv Rev (1999) 35:307–35.10.1016/S0169-409X(98)00079-9 PubMed DOI

Borgono CA, Zinman B. Insulins: past, present, and future. Endocrinol Metab Clin North Am (2012) 41:1–24.10.1016/j.ecl.2012.03.002 PubMed DOI

Niswender KD. Basal insulin: physiology, pharmacology, and clinical implications. Postgrad Med (2011) 123:17–26.10.3810/pgm.2011.07.2300 PubMed DOI

Herring R, Jones RH, Russell-Jones DL. Hepatoselectivity and the evolution of insulin. Diabetes Obes Metab (2014) 16:1–8.10.1111/dom.12117 PubMed DOI

Olson AL, Pessin JE. Structure, function, and regulation of the mammalian facilitative glucose transporter gene family. Annu Rev Nutr (1996) 16:235–56.10.1146/annurev.nu.16.070196.001315 PubMed DOI

Joost HG, Thorens B. The extended GLUT-family of sugar/polyol transport facilitators: nomenclature, sequence characteristics, and potential function of its novel members. Mol Membr Biol (2001) 18:247–56.10.1080/09687680110090456 PubMed DOI

Madsbad S. LY2605541-A preferential hepato-specific insulin analogue. Diabetes (2014) 63:390–2.10.2337/db13-1646 PubMed DOI

Hirose T. Development of new basal insulin peglispro (LY2605541) ends in a disappointing result. Diabetol Int (2016) 7:16–7.10.1007/s13340-016-0255-1 PubMed DOI PMC

Vienberg SG, Bouman SD, Sorensen H, Stidsen CE, Kjeldsen T, Glendorf T, et al. Receptor-isoform-selective insulin analogues give tissue-preferential effects. Biochem J (2011) 440:301–8.10.1042/BJ20110880 PubMed DOI

Westermeier F, Saez T, Arroyo P, Toledo F, Gutierrez J, Sanhueza C, et al. Insulin receptor isoforms: an integrated view focused on gestational diabetes mellitus. Diabetes Metab Res Rev (2016) 32:350–65.10.1002/dmrr.2729 PubMed DOI

LeRoith D, Werner H, Beitnerjohnson D, Roberts CT. Molecular and cellular aspects of the insulin-like growth-factor-I receptor. Endocr Rev (1995) 16:143–63.10.1210/edrv-16-2-143 PubMed DOI

LeRoith D. The insulin-like growth factor system. Exp Diabesity Res (2003) 4:205–12.10.1155/EDR.2003.205 PubMed DOI PMC

Boucher J, Kleinridders A, Kahn CR. Insulin receptor signaling in normal and insulin-resistant states. Cold Spring Harb Perspect Biol (2014) 6:1–24.10.1101/cshperspect.a009191 PubMed DOI PMC

Pan HF, Finkel T. Key proteins that regulate lifespan. J Biol Chem (2017) 292:6452–60.10.1074/jbc.R116.771915 PubMed DOI PMC

Renehan AG, Frystyk J, Flyvbjerg A. Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab (2006) 17:328–36.10.1016/j.tem.2006.08.006 PubMed DOI

Brody H, DeWeerdt S, Greenbaum C, Gravitz L, Mandrup-Poulsen T, Scully T. Diabetes. Nature (2012) 485(7398):S1–19.10.1038/485S1a PubMed DOI

Bailyes EM, Nave BT, Soos MA, Orr SR, Hayward AC, Siddle K. Insulin receptor/IGF-1 receptor hybrids are widely distributed in mammalian tissues: quantification of individual receptor species by selective immunoprecipitation and immunoblotting. Biochem J (1997) 327:209–15.10.1042/bj3270209 PubMed DOI PMC

Slaaby R. Specific insulin/IGF1 hybrid receptor activation assay reveals IGF1 as a more potent ligand than insulin. Sci Rep (2015) 5:7911.10.1038/srep07911 PubMed DOI PMC

Slaaby R, Schaffer L, Lautrup-Larsen I, Andersen AS, Shaw AC, Mathiasen IS, et al. Hybrid receptors formed by insulin receptor (IR) and insulin-like growth factor I receptor (IGF-IR) have low insulin and high IGF-1 affinity irrespective of the IR splice variant. J Biol Chem (2006) 281:25869–74.10.1074/jbc.M605189200 PubMed DOI

Clemmons DR. Role of IGF binding proteins in regulating metabolism. Trends Endocrinol Metab (2016) 27:375–91.10.1016/j.tem.2016.03.019 PubMed DOI

Williams C, Hoppe HJ, Rezgui D, Strickland M, Forbes BE, Grutzner F, et al. An exon splice enhancer primes IGF2:IGF2R binding site structure and function evolution. Science (2012) 338:1209–13.10.1126/science.1228633 PubMed DOI PMC

Vikova J, Collinsova M, Kletvikova E, Budesinsky M, Kaplan V, Zakova L, et al. Rational steering of insulin binding specificity by intra-chain chemical crosslinking. Sci Rep (2016) 6:19431.10.1038/srep19431 PubMed DOI PMC

Krizkova K, Chrudinova M, Povalova A, Selicharova I, Collinsova M, Vanek V, et al. Insulin-insulin-like growth factors hybrids as molecular probes of hormone: receptor binding specificity. Biochemistry (2016) 55:2903–13.10.1021/acs.biochem.6b00140 PubMed DOI

Hexnerova R, Krizkova K, Fabry M, Sieglova I, Kedrova K, Collinsova M, et al. Probing receptor specificity by sampling the conformational space of the insulin-like growth factor II C-domain. J Biol Chem (2016) 291:21234–45.10.1074/jbc.M116.741041 PubMed DOI PMC

Denley A, Bonython ER, Booker GW, Cosgrove LJ, Forbes BE, Ward CW, et al. Structural determinants for high-affinity binding of insulin-like growth factor II to insulin receptor (IR)-A, the exon 11 minus isoform of the IR. Mol Endocrinol (2004) 18:2502–12.10.1210/me.2004-0183 PubMed DOI

Andersen M, Nørgaard-Pedersen D, Brandt J, Pettersson I, Slaaby R. IGF1 and IGF2 specificities to the two insulin receptor isoforms are determined by insulin receptor amino acid 718. PLoS One (2017) 12:e017885.10.1371/journal.pone.0178885 PubMed DOI PMC

Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell (2010) 141:1117–34.10.1016/j.cell.2010.06.011 PubMed DOI PMC

Bhattacharya A. Protein structures: structures of desire. Nature (2009) 459:24–7.10.1038/459024a PubMed DOI

Siddle K. Molecular basis of signaling specificity of insulin and IGF receptors: neglected corners and recent advances. Front Endocrinol (2012) 3:34.10.3389/fendo.2012.00034 PubMed DOI PMC

Versteyhe S, Klaproth B, Borup R, Palsgaard J, Jensen M, Gray SG, et al. IGF-I, IGF-II, and insulin stimulate different gene expression responses through binding to the IGF-I receptor. Front Endocrinol (2013) 4:98.10.3389/fendo.2013.00098 PubMed DOI PMC

Cai WK, Sakaguchi M, Kleinridders A, Gonzalez-Del Pino G, Dreyfuss JM, O’Neill BT, et al. Domain-dependent effects of insulin and IGF-1 receptors on signalling and gene expression. Nat Commun (2017) 8:14892.10.1038/ncomms14892 PubMed DOI PMC

Yamaguchi Y, Flier JS, Benecke H, Ransil BJ, Moller DE. Ligand-binding properties of the two isoforms of the human insulin receptor. Endocrinology (2017) 132:1132–8.10.1210/endo.132.3.8440175 PubMed DOI

Yamaguchi Y, Flier JS, Yokota A, Benecke H, Backer JM, Moller DE. Functional properties of two naturally occurring isoforms of the human insulin receptor in Chinese hamster ovary cells. Endocrinology (1991) 129:2058–66.10.1210/endo-129-4-2058 PubMed DOI

Mosthaf L, Grako K, Dull TJ, Coussens L, Ullrich A, Mcclain DA. Functionally distinct insulin-receptors generated by tissue-specific alternative splicing. EMBO J (1990) 9:2409–13. PubMed PMC

Chen DY, Stern SA, Garcia-Osta A, Saunier-Rebori B, Pollonini G, Bambah-Mukku D, et al. A critical role for IGF-II in memory consolidation and enhancement. Nature (2011) 469:491–7.10.1038/nature09667 PubMed DOI PMC

Dynkevich Y, Rother KI, Whitford I, Qureshi S, Galiveeti S, Szulc AL, et al. Tumors, IGF-2, and hypoglycemia: insights from the clinic, the laboratory, and the historical archive. Endocr Rev (2013) 34:798–826.10.1210/er.2012-1033 PubMed DOI

Vigneri R, Goldfine ID, Frittitta L. Insulin, insulin receptors, and cancer. J Endocrinol Invest (2016) 39:1365–76.10.1007/s40618-016-0508-7 PubMed DOI

McKern NM, Lawrence MC, Streltsov VA, Lou MZ, Adams TE, Lovrecz GO, et al. Structure of the insulin receptor ectodomain reveals a folded-over conformation. Nature (2006) 443:218–21.10.1038/nature05106 PubMed DOI

Lou MZ, Garrett TPJ, McKern NM, Hoyne PA, Epa VC, Bentley JD, et al. The first three domains of the insulin receptor differ structurally from the insulin-like growth factor 1 receptor in the regions governing ligand specificity. Proc Natl Acad Sci U S A (2006) 103:12429–34.10.1073/pnas.0605395103 PubMed DOI PMC

Menting JG, Whittaker J, Margetts MB, Whittaker LJ, Kong GKW, Smith BJ, et al. How insulin engages its primary binding site on the insulin receptor. Nature (2013) 493:241–5.10.1038/nature11781 PubMed DOI PMC

Menting JG, Yang YW, Chan SJ, Phillips NB, Smith BJ, Whittaker J, et al. Protective hinge in insulin opens to enable its receptor engagement. Proc Natl Acad Sci U S A (2014) 111:E3395–404.10.1073/pnas.1412897111 PubMed DOI PMC

Menting JG, Lawrence CF, Kong GKW, Margetts MB, Ward CW, Lawrence MC. Structural congruency of ligand binding to the insulin and insulin/type 1 insulin-like growth factor hybrid receptors. Structure (2015) 23:1271–82.10.1016/j.str.2015.04.016 PubMed DOI

Brzozowski AM, Dodson EJ, Dodson GG, Murshudov GN, Verma C, Turkenburg JP, et al. Structural origins of the functional divergence of human insulin-like growth factor-I and insulin. Biochemistry (2002) 41:9389–97.10.1021/bi020084j PubMed DOI

Keyhanfar M, Booker GW, Whittaker J, Wallace JC, Forbes BE. Precise mapping of an IGF-I-binding site on the IGF-1R. Biochem J (2007) 401:269–77.10.1042/BJ20060890 PubMed DOI PMC

Glendorf T, Stidsen CE, Norrman M, Nishimura E, Sorensen AR, Kjeldsen T. Engineering of insulin receptor isoform-selective insulin analogues. PLoS One (2011) 6(5):e20288.10.1371/journal.pone.0020288 PubMed DOI PMC

Zakova L, Kletvikova E, Lepsik M, Collinsova M, Watson CJ, Turkenburg JP, et al. Human insulin analogues modified at the B26 site reveal a hormone conformation that is undetected in the receptor complex. Acta Crystallogr D Biol Crystallogr (2014) 70:2765–74.10.1107/S1399004714017775 PubMed DOI PMC

A viral insulin-like peptide inhibits IGF-1 receptor phosphorylation and regulates IGF1R gene expression

Characterization of viral insulins reveals white adipose tissue-specific effects in mice

A radioligand binding assay for the insulin-like growth factor 2 receptor

Mutations at hypothetical binding site 2 in insulin and insulin-like growth factors 1 and 2 result in receptor- and hormone-specific responses